Company news
Ionis Pharmaceuticals, Inc. news in 2021
Ionis Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.
Ionis and AstraZeneca close deal to develop and commercialize eplontersen
December 28, 2021
Ionis and AstraZeneca to develop and commercialize eplontersen
December 6, 2021
Ionis to hold virtual investor day event
December 1, 2021
Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen
November 23, 2021
Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema
November 17, 2021
Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021
November 11, 2021
Ionis to present at upcoming virtual investor conferences
November 8, 2021
Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting
November 6, 2021
Ionis reports third quarter 2021 financial results and recent business achievements
November 2, 2021
Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia
November 1, 2021
Ionis to hold third quarter 2021 financial results webcast
October 19, 2021
Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
October 16, 2021
Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting
September 2, 2021
Ionis reports second quarter 2021 financial results and recent business achievements
August 3, 2021
Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen
July 28, 2021
Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology
July 12, 2021
Ionis' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award in Biotechnology and Medicine
June 13, 2021
Ionis announces changes to its board of directors at annual meeting of stockholders
June 1, 2021
Ionis reports first quarter 2021 financial results and recent business achievements
May 4, 2021
Ionis initiates pivotal clinical study of novel antisense medicine to treat patients with Alexander disease
April 19, 2021
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
April 4, 2021
Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema
March 28, 2021
Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis
February 28, 2021
Ionis reports fourth quarter and full year 2020 financial results and recent business achievements
February 23, 2021
Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
January 6, 2021
Calls in 2021
- Ionis Pharmaceuticals (NASDAQ:IONS) Q3 2021 Earnings Call
Nov 3, 2021
Transcript - Ionis Pharmaceuticals (NASDAQ:IONS) Q2 2021 Earnings Call
Aug 4, 2021
Transcript - Ionis Pharmaceuticals (NASDAQ:IONS) Q1 2021 Earnings Call
May 5, 2021
Transcript - Ionis Pharmaceuticals (NASDAQ:IONS) Q4 2020 Earnings Call
Feb 24, 2021
Transcript